Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597414 | 0.87 | ELANE (0.64) | ELANENAMPT | |
| SCHEMBL4126035 | 0.85 | ELANE (0.74) | ELANE | |
| SCHEMBL4134848 | 0.82 | ELANE (0.70) | ELANE | |
| SCHEMBL31495992 | 0.81 | ELANE (0.70) | ELANE | |
| SCHEMBL4022133 | 0.81 | ELANE (0.70) | ELANE | |
| SCHEMBL597437 | 0.80 | ELANE (0.62) | ELANENAMPT | |
| SCHEMBL23925515 | 0.79 | ELANE (0.72) | ELANENAMPT | |
| Alvelestat SCHEMBL560757 | 0.79 | ELANE (1.00) | ELANE | |
| Alvelestat SCHEMBL30179302 | 0.79 | ELANE (1.00) | ELANE | |
| Alvelestat SCHEMBL29740084 | 0.79 | ELANE (1.00) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410114-B2 | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial | ASTRAZENECA AB (SE) | 2013-04-02 | — | — | US | disclosed |
| US-20120108610-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-8114881-B2 | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial | ASTRAZENECA AB (SE) | 2012-02-14 | — | — | US | disclosed |
| US-20090209555-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
| EP-2018377-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL. | Astra Zeneca AB (SE) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007129963-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL. | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209555-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | SERPINB1, ELANE, EPX | ELANE 2/4885NAMPT 1549/4885 |
| US-20120108610-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | SERPINB1, ELANE, EPX | ELANE 2/4885NAMPT 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.